Breast Cancer: Blocking both driver and escape pathways improves outcomes

Nature Reviews Clinical Oncology

Volumn 9, Issue 3, 2012, Pages 133-134

  Rimawi, Mothaffar F ^a   Osborne, C Kent ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE INHIBITOR; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; EVEROLIMUS; EXEMESTANE; LAPATINIB; MAMMALIAN TARGET OF RAPAMYCIN; PERTUZUMAB; PHOSPHATIDYLINOSITOL 3 KINASE; PLACEBO; PROTEIN KINASE B; TRASTUZUMAB;

ADVANCED CANCER; ANEMIA; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL EFFECTIVENESS; DIARRHEA; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; EARLY CANCER; ENZYME INHIBITION; FATIGUE; FEBRILE NEUTROPENIA; HUMAN; HYPERGLYCEMIA; METASTASIS; MOLECULARLY TARGETED THERAPY; MOUTH PAIN; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PNEUMONIA; PRIMARY HEALTH CARE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; SHORT SURVEY; SIGNAL TRANSDUCTION; TREATMENT DURATION; TUMOR ESCAPE;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; SIROLIMUS; WOMEN'S HEALTH;

EID: 84857918667     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2012.9     Document Type: Short Survey

References (10)

1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 378, 771-784 (2011).
2. Perez, E. A. et al. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J. Clin. Oncol. 29, 3366-3373 (2011).
3. Baselga, J. et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N. Engl. J. Med. http://dx.doi.org/10.1056/ NEJMoa1109653.
4. Baselga, J. et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N. Engl. J. Med. 366, 109-119 (2012).
5. Ghosh, R. et al. Trastuzumab has preferential activity against breast cancers driven by HER2 homodimers. Cancer Res. 71, 1871-1882 (2011).
6. Osborne, C. K. & Schiff, R. Mechanisms of endocrine resistance in breast cancer. Annu. Rev. Med. 62, 233-247 (2011).
7. Creighton, C. J. et al. Development of resistance to targeted therapies transforms the clinically associated molecular profile subtype of breast tumor xenografts. Cancer Res. 68, 7493-7501 (2008).
8. Rimawi, M. F. et al. Reduced dose and intermittent treatment with lapatinib and trastuzumab for potent blockade of the HER pathway in HER2/neu-overexpressing breast tumor xenografts. Clin. Cancer Res. 17, 1351-1361 (2011).
9. Chang, J. C. N. et al. TBCRC 006: A multicenter phase II study of neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2-overexpressing breast cancer [abstract]. J. Clin. Oncol. 29 (Suppl.), a505 (2011).
10. Gianni, L. et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 13, 25-32 (2012).